Market Closed -
Hong Kong S.E.
09:08:20 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
27.4
HKD
|
-0.90%
|
|
-0.90%
|
-4.20%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
4,606
|
5,714
|
3,111
|
4,266
|
4,445
|
4,441
|
-
|
-
|
Enterprise Value (EV)
1 |
4,606
|
5,714
|
3,111
|
4,266
|
4,445
|
4,441
|
4,441
|
4,441
|
P/E ratio
|
35.1
x
|
47.2
x
|
21.8
x
|
32.6
x
|
28.3
x
|
21.9
x
|
16.7
x
|
13.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
16.1
x
|
15.9
x
|
-
|
7.28
x
|
5.9
x
|
4.54
x
|
3.46
x
|
2.67
x
|
EV / Revenue
|
16.1
x
|
15.9
x
|
-
|
7.28
x
|
5.9
x
|
4.54
x
|
3.46
x
|
2.67
x
|
EV / EBITDA
|
-
|
42,534,660
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-68
x
|
-
|
96.6
x
|
27.8
x
|
20.1
x
|
FCF Yield
|
-
|
-
|
-
|
-1.47%
|
-
|
1.04%
|
3.6%
|
4.98%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
166,000
|
166,000
|
166,000
|
168,000
|
170,998
|
175,107
|
-
|
-
|
Reference price
2 |
27.75
|
34.42
|
18.74
|
25.39
|
25.99
|
25.36
|
25.36
|
25.36
|
Announcement Date
|
19/03/20
|
19/03/21
|
18/03/22
|
20/03/23
|
18/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
286.5
|
358.4
|
-
|
585.9
|
752.8
|
979
|
1,282
|
1,664
|
EBITDA
|
-
|
134.3
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
112.4
|
-
|
145.3
|
178.3
|
208
|
272
|
347
|
Operating Margin
|
-
|
31.35%
|
-
|
24.8%
|
23.69%
|
21.25%
|
21.22%
|
20.85%
|
Earnings before Tax (EBT)
1 |
-
|
137.1
|
-
|
144.5
|
175.1
|
206
|
270
|
345
|
Net income
1 |
-
|
121.4
|
143
|
131.7
|
153.2
|
199
|
260
|
331
|
Net margin
|
-
|
33.86%
|
-
|
22.48%
|
20.35%
|
20.33%
|
20.28%
|
19.89%
|
EPS
2 |
0.7900
|
0.7300
|
0.8600
|
0.7800
|
0.9200
|
1.160
|
1.520
|
1.940
|
Free Cash Flow
1 |
-
|
-
|
-
|
-62.75
|
-
|
46
|
160
|
221
|
FCF margin
|
-
|
-
|
-
|
-10.71%
|
-
|
4.7%
|
12.48%
|
13.28%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
23.12%
|
61.54%
|
66.77%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
19/03/21
|
18/03/22
|
20/03/23
|
18/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-62.7
|
-
|
46
|
160
|
221
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
11.4%
|
13.7%
|
15.8%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
243
|
-
|
150
|
100
|
100
|
Capex / Sales
|
-
|
-
|
-
|
41.51%
|
-
|
15.32%
|
7.8%
|
6.01%
|
Announcement Date
|
19/03/20
|
19/03/21
|
18/03/22
|
20/03/23
|
18/03/24
|
-
|
-
|
-
|
Last Close Price
25.36
CNY Average target price
32.25
CNY Spread / Average Target +27.14% Consensus |
1st Jan change
|
Capi.
|
---|
| -4.20% | 613M | | +12.07% | 128B | | -9.04% | 10.65B | | +0.91% | 8.82B | | +16.72% | 7.19B | | +25.15% | 4.99B | | +7.17% | 3.4B | | -1.36% | 3.03B | | -8.73% | 2.14B | | -10.15% | 2B |
Medical Devices & Implants
|